Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by toniZ1on Apr 13, 2022 11:06am
98 Views
Post# 34600334

RE:RE:RE:Ho Hum

RE:RE:RE:Ho Humhehe, yes painfull to wait.... think in regards to their history there is simply no trust and so no intrest. yes don't expect anything from the dermal injector. if I am wrong and there is value in it be happy, but don't count on it.... worst outcome is, shiseido returns the license and says finally good bye - if that happens drop it as fast as you can. but as i already had pointed out I expect the opposite, they were willing to run a 2nd trail and that was enough evidence for me...

max 6 months to go, but I expect things will be clear within the next 3 months...don't expect anything else of importance happening until then.

the share price... makes it rly a difference if it is at 0.15 or 0.20? at least not for long termers... lets stay strong for last part of the path, the decision is near...




<< Previous
Bullboard Posts
Next >>